Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Real-World Experience with Tofacitinib in IBD at a Tertiary Center.

Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT.

Dig Dis Sci. 2019 Feb 7. doi: 10.1007/s10620-019-05492-y. [Epub ahead of print]

PMID:
30734234
2.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
3.

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.

Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31278-3. doi: 10.1016/j.cgh.2018.11.035. [Epub ahead of print]

4.

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029. Epub 2014 Jan 27.

PMID:
24480677
5.

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Danese S, Grisham M, Hodge J, Telliez JB.

Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155-62. doi: 10.1152/ajpgi.00311.2015. Epub 2015 Nov 25. Review.

6.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

7.

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.

Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P.

BMC Gastroenterol. 2015 Feb 5;15:14. doi: 10.1186/s12876-015-0239-9.

8.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.

Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

9.

Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.

Beattie DT, Pulido-Rios MT, Shen F, Ho M, Situ E, Tsuruda PR, Brassil P, Kleinschek M, Hegde S.

J Inflamm (Lond). 2017 Dec 6;14:28. doi: 10.1186/s12950-017-0175-2. eCollection 2017.

10.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
11.

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.

Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10.

12.

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.

Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU.

Am J Gastroenterol. 2006 May;101(5):1048-56.

PMID:
16573777
13.

Fecal transplantation for treatment of inflammatory bowel disease.

Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, Acra S.

Cochrane Database Syst Rev. 2018 Nov 13;11:CD012774. doi: 10.1002/14651858.CD012774.pub2. Review.

PMID:
30480772
14.

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators.

N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.

15.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators.

Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4.

PMID:
26051365
16.

The use of tofacitinib in the treatment of inflammatory bowel disease.

Weisshof R, Golan MA, Yvellez OV, Rubin DT.

Immunotherapy. 2018 Aug;10(10):837-849. doi: 10.2217/imt-2018-0015. Epub 2018 Apr 27.

PMID:
29701124
18.

Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.

Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.

Br J Clin Pharmacol. 2018 Jun;84(6):1136-1145. doi: 10.1111/bcp.13523. Epub 2018 Mar 23.

19.

Methotrexate for induction of remission in ulcerative colitis.

Chande N, Wang Y, MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2014 Aug 27;(8):CD006618. doi: 10.1002/14651858.CD006618.pub3. Review.

PMID:
25162749
20.

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.

Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S.

Arthritis Res Ther. 2016 Jan 28;18:34. doi: 10.1186/s13075-016-0932-2.

Supplemental Content

Support Center